Biogen Inc. $BIIB Shares Bought by NEOS Investment Management LLC

NEOS Investment Management LLC raised its stake in Biogen Inc. (NASDAQ:BIIB) by 55.7% in the third quarter, HoldingsChannel reports. The institutional investor owned 57,301 shares of the biotechnology company’s stock after buying an additional 20,490 shares during the quarter. NEOS Investment Management LLC’s holdings in Biogen were worth $8,027,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Elevation Point Wealth Partners LLC acquired a new position in Biogen during the second quarter worth $25,000. Rothschild Investment LLC grew its holdings in Biogen by 64.7% in the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 88 shares during the last quarter. NewSquare Capital LLC increased its position in shares of Biogen by 134.6% in the second quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 140 shares in the last quarter. WFA of San Diego LLC acquired a new position in shares of Biogen during the 2nd quarter worth $32,000. Finally, True Wealth Design LLC boosted its position in shares of Biogen by 62.9% in the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after buying an additional 90 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Trading Down 0.8%

Shares of Biogen stock opened at $194.13 on Thursday. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The business’s fifty day moving average is $179.27 and its two-hundred day moving average is $160.46. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The firm has a market cap of $28.49 billion, a PE ratio of 22.04, a P/E/G ratio of 1.55 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business’s revenue for the quarter was down 7.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. HSBC restated a “reduce” rating and set a $143.00 target price (down from $144.00) on shares of Biogen in a report on Wednesday, December 10th. UBS Group assumed coverage on shares of Biogen in a research note on Tuesday, January 6th. They set a “neutral” rating and a $185.00 price objective for the company. Wolfe Research set a $231.00 target price on Biogen in a research note on Monday, February 9th. Robert W. Baird dropped their price target on Biogen from $255.00 to $250.00 in a research report on Friday, October 31st. Finally, BMO Capital Markets boosted their price target on Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a report on Friday, February 6th. Twelve investment analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company. According to MarketBeat, Biogen has an average rating of “Hold” and an average price target of $205.84.

Insider Transactions at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This represents a 24.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.18% of the company’s stock.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.